Effect of exercise and diet intervention in NAFLD and NASH via GAB2 methylation

Na Wu1,3, Fan Yuan1,3, Siran Yue2, Fengyan Jiang2, Decheng Ren1,3, Liangjie Liu1,3, Yan Bi1,3, Zhenming Guo1,3, Lei Ji1,3, Ke Han1,3, Xiao Yang1,3, Mofan Feng1,3, Kai Su1,3, Fengping Yang1,3, Xi Wu1,3, Qing Lu1,3, Xingwang Li1,3, Ruirui Wang2, Baoceng Liu2, Shenglong Le4, Yi Shi1,3* and Guang He1,3*

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) is a disorder that extends from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH), which is effectively alleviated by lifestyle intervention. Nevertheless, DNA methylation mechanism underlying the effect of environmental factors on NAFLD and NASH is still obscure. The aim of this study was to investigate the effect of exercise and diet intervention in NAFLD and NASH via DNA methylation of GAB2.

Methods: Methylation of genomic DNA in human NAFLD was quantified using Infinium Methylation EPIC BeadChip assay after exercise (Ex), low carbohydrate diet (LCD) and exercise plus low carbohydrate diet (ELCD) intervention. The output Idat files were processed using ChAMP package. False discovery rate on genome-wide analysis of DNA methylation (q < 0.05), and cytosine-guanine dinucleotides (CpGs) which are located in promoters were used for subsequent analysis (|Δβ| ≥ 0.1). K-means clustering was used to cluster differentially methylated genes according to 3D genome information from Human embryonic stem cell. To quantify DNA methylation and mRNA expression of GAB2 associated binding protein 2 (GAB2) in NASH mice after Ex, low fat diet (LFD) and exercise plus low fat diet (ELFD), MassARRAY EpiTYPER and quantitative reverse transcription polymerase chain reaction were used.

Results: Both LCD and ELCD intervention on human NAFLD can induce same DNA methylation alterations at critical genes in blood, e.g., GAB2, which was also validated in liver and adipose of NASH mice after LFD and ELFD intervention. Moreover, methylation of CpG units (i.e., CpG_10.11.12) inversely correlated with mRNA expression GAB2 in adipose tissue of NASH mice after ELFD intervention.

Conclusions: We highlighted the susceptibility of DNA methylation in GAB2 to ELFD intervention, through which exercise and diet can protect against the progression of NAFLD and NASH on the genome level, and demonstrated that the DNA methylation variation in blood could mirror epigenetic signatures in target tissues of important biological function, i.e., liver and adipose tissue.

Trial registration International Standard Randomized Controlled Trial Number Register (ISRCTN42622771)

Keywords: NAFLD, NASH, Exercise intervention, Diet intervention, DNA methylation, GAB2

Introduction

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) can increase the risk of hepatocellular carcinoma, type 2 diabetes and cardiovascular diseases [2–4], which are known to be the most common causes of mortality worldwide [5]. It was estimated that the NAFLD and NASH population in China...
would increase by 26.2% and 48% by 2030, respectively [6].

Previous studies have shown that exercise and diet play important roles in the treatment of NAFLD and NASH [7, 8]. The reduction in triglyceride, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were observed in NASH patients after 1-year dietary intervention [9]. Promrat et al. [10] also found that NASH histological activity score (NAS) was improved after 48 weeks of diet and exercise intervention. Cheng et al. [11] revealed that liver steatosis was reduced in NAFLD patients after exercise training combined with low carbohydrate diet. All above findings demonstrated that lifestyle intervention is an effective way to treat NAFLD, while the underlying epigenetic mechanism remains obscure.

Recently, epigenetic phenomena such as DNA methylation is considered to be involved in the occurrence and development of NAFLD and NASH [12–15], providing a pathway in translating environmental factors into phenotypic traits [16]. Only a few studies have reported the DNA methylation profiles after lifestyle interventions in NAFLD [17–19]. Yaskolka et al. [19] suggested that differential DNA methylation of alpha-2-macroglobulin pseudogene 1 (A2MP1) and calcium release activated channel regulator 2 (ACRACR2A) in blood could be the epigenetic markers for intrahepatic fat in NAFLD patients after diet and physical activity intervention, respectively. Yoon et al. [18] reported that DNA methylation of caspase 1 (CASP1) and NADH dehydrogenase 1 beta subcomplex 9 (NDUFB9) were downregulated and upregulated in liver of obese mice respectively, in response to high fat diet (HFD) compared with the control diet. Notably, DNA methylation occurs under a highly tissue specific manner [20]. In view of the difficulty of acquisition of human tissues, e.g., liver and adipose tissue, blood usually was used as a substitute to investigate whether the DNA methylation marker could reflect the signature cross tissues. And Dick et al. demonstrated that body mass index (BMI) was positively associated with DNA methylation of hypoxia inducible factor 3 alpha subunit (HIF3A) both in blood and adipose tissue. Nevertheless, it is still unclear what are the detailed DNA methylation mechanisms behind the long-lasting effects of separate aerobic exercise, low carbohydrate diet (LCD) or low fat diet (LFD) and the combination of exercise and diet, especially in blood, liver and adipose tissue of NAFLD and NASH.

Given the increasing evidences of the DNA methylation involvement in metabolic diseases, and considering DNA methylation playing intriguing roles in exercise and diet related prevention and treatment of NAFLD and NASH, we aim to: (1) explore genome wide DNA methylation changes before and after exercise and LCD intervention in human NAFLD; (2) investigate the effect of respective and concurrent exercise and LFD intervention on DNA methylation of candidate genes in blood of NAFLD and evaluate these effect in liver and adipose tissue of NASH mice; (3) reveal the correlations between DNA methylation of candidate gene and clinical phenotypes after intervention.

Materials and methods

Human trial

Study participants

This work is an extension of our previous study on exercise and diet intervention in NAFLD population [11, 21]. Male or female aged 50–65 years with hepatic fat content (HFC) >5% [22], BMI ≤ 38 kg/m², no alcohol consumption, no chronic cardiovascular or musculoskeletal diseases, no type I/II diabetes and no mental illness were included in this trial. And they were randomly assigned (1:1:1:1) to exercise (Ex, n = 29), LCD (LCD, n = 28) and exercise plus diet intervention (ELCD = 29), and no intervention (No = 29) groups for minimal 6 months. A subgroup comprising 32 female aged 50–65 years with NAFLD was finally included, and they were selected on the basis of HFC decline in the Ex (n = 8), LCD (n = 8) and ELCD (n = 9) groups, or HFC gain in No (n = 7) group for minimal 6 months (Additional file 1).

The Ex and ELCD groups participated an aerobic exercise training program under the supervision of exercise trainers [11]. The intensity was ranged from 60 to 75% of the maximum oxygen uptake (VO₂max), 30 to 60 min per session which included the warm-up and cool-down exercise for 5 min, respectively, and the frequency was 2 to 3 times per week.

The LFD and ELFD groups were offered a daily lunch based on each subject’s dietary intakes and body weight, and were advised to follow an individual nutritional consultation program for breakfast and dinner [11]. The daily lunch was accounted 30–40% of their total daily energy intake, in particular, 37–40% carbohydrate, 35–37% fat and 25–27% protein.

The no intervention group (No) was suggested to keep their physical activity and dietary habits the same during the intervention.

Measurement

Collection of phenotypes including lifestyle and medical history information, anthropometry, body composition, HFC, abdominal subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) were reported in our previous study [11]. Lifestyle and medical history were collected by questionnaires. Fat mass (FM) and lean mass (LM) of the whole body, and android and gynoid regions were assessed by dual-energy X-ray...
absorptiometry (DXA Prodigy, GE Lunar Corp., Madison, WI USA). HFC, SAT and VAT was measured by 1H MRS [23, 24]. BMI was calculated as weight (kg) divided by height squared (m²).

Insulin and glucose were assessed from glucose tolerance test (performed after overnight fasting and 2 h after the intake of 75 g glucose). Total cholesterol and triglycerides were measured from serum by conventional methods [21].

**Genome-wide DNA methylation analysis**

DNA was extracted from peripheral blood; methylation of genomic DNA was quantified using Infinium Methylation EPIC BeadChip assay (Illumina, CA, USA), which covers 865,918 CpGs [25]. After bisulfite-converting the genomic DNA samples with Zymo EZ DNA Methylation-Gold Kit (Zymo Research, Orange, CA, USA), pre- and post-amplification automated laboratory protocols were performed according to the Infinium HD methylation Assay Guide [26–28]. The BeadChips’ images were captured with the Illumina iScan. Raw methylation score for each CpG site expressed as β-values was calculated (β = intensity of the Methylated allele (M)/intensity of the Unmethylated allele (U) + intensity of the Methylated allele (M) + 100) with Genome Studio software (version 2011.1). The output Idat files were processed using ChAMP data package (version 2.8.1). After loading Idat files, several filtering steps were preformed: (1) Discard the sample with probes’ ratio above threshold (default = 0.1); (2) Filter out probes with <3 beads in at least 5% of samples per probe and all non-CpG probes contained in this dataset; (3) Exclude all SNP-related probes, multi-hit probes or probes located in chromosome X and Y to improve the hybridization efficiency and explore the true signals [29, 30]. Next, normalization with BMIQ function was conducted to adjust the effects of type-II probe bias. To account for multiple testing and reduce the number of false positives, we applied the false discovery rate (FDR) on our genome-wide analysis and explore the true signals [29, 30]. Next, normalization with BMIQ function was conducted to adjust the effects of type-II probe bias. To account for multiple testing and reduce the number of false positives, we applied the

|3D genome [32]|

3D genome information from human embryonic stem cell [33] was built through high-throughput chromosome conformation capture (Hi-C) technology. As genes with adjacent position of chromosome had similar function [34], k-means clustering method was firstly used to cluster differentially methylated genes from the aspect of gene structure/location according to 3D genome of human cells. Then, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was performed with the R package clusterProfiler [35] and q value less than 0.05 was considered statistically significant. We also constructed the KEGG pathway gene interaction network using the STRING database, and visualize the pathways with igraph and ggraph R packages. By this double-fisted approach combined with 3D genome information and KEGG enrichment analysis, the most differentially methylated genes could be selected.

**Animal experiment**

**Experimental design**

Seventy C57BL/6 male mice with specific pathogen free (SPF) grades, aged 9 weeks were used in this study. After acclimating to their environment for 1 week, weight ≥ 25 g, all animals had free access to food and tap water at a pathogen free animal care facility. At 10 weeks of age, the mice were randomly assigned to either a methionine choline deficient diet (MCD, #519580, Dyets, n = 55) or a methionine choline sufficient diet (MCS, #519581, Dyets, n = 15) group, respectively, for 4 weeks. After 4 weeks, 7 mice in each group were sacrificed when finishing an exercise training to evaluate their exercise adaptability and check whether they are NASH mice. Then NASH mice were randomly assigned to 6 groups for 4 weeks of intervention period: feeding with HFD (#D12492, Research Diets, n = 8), aerobic exercise plus HFD (EHFD, n = 8), LD (LF10C, Dyets, n = 8), aerobic exercise plus LFD (ELFD, n = 8), MCS diet (MCSM, n = 8), MCD diet (MCD, n = 8). The control group remained to MCS diet (MCS, n = 8).

Exercise training was performed on a motor-driven rodent treadmill. For 5 days acclimation, mice in the EHFD and ELFD groups ran 10 min at a speed of 10 m/min on Monday, 13 m/min for 25 min on Tuesday, 14 m/min for 35 min on Wednesday, 15 m/min for 45 min on Thursday and Friday, then had rest for 2 days. In the end, mice ran 15 m/min for 45 min for 4 weeks, at a frequency of 5 days/week. Food intake and body weight were recorded twice and once a week for the entire period of the study, respectively.

After 4 weeks of intervention, the blood was obtained when the mice were sacrificed; the serum was stored at −80 °C for the biochemical analysis. Liver and epididymal fat tissues were collected and weighed. Aliquots were snap frozen and stored at −80 °C. Part of the liver tissue was fixed in 4% buffered paraformaldehyde and...
processed and embedded in paraffin for histological analysis. Liver sections were stained with haematoxylin and eosin (HE) for routine histology or with oil red O for detection of lipids.

Biochemical assay
Total cholesterol, triglyceride, serum ALT and AST levels were measured using automated clinical chemistry analyser (7020, HITACHI, Japan) in the Laboratory of Animal Centre, Shanghai University of Traditional Chinese Medicine.

DNA methylation analysis
Genomic DNA was isolated from mice liver and adipose tissue using a TIANamp Genomic DNA Kit (#DP304, TIANGEN, China). Bisulfite conversion of genomic DNA was performed using the EpiTect Fast Bisulfite Conversion Kit (#59824, Qiagen, Germany). The CpG island region was selected to analyze the CpG methylation level. Target-specific primer pairs to amplify bisulfite-treated genomic DNA were designed using the EpiDesigner tool (Agena Bioscience, Inc., San Diego, CA, USA). Primers were synthesized by Generay, and each reverse primer had a T7 promoter tag (5′-CAG TAA TAC GAC TCA CTA 3′) for transcription. The forward primer was tagged with a 10-mer (5′-AGGAAGAGAG-3′) to balance the melting temperature. The polymerase chain reaction (PCR)-amplified products were treated with shrimp alkaline phosphatase, and in vitro transcription and base-specific cleavage were performed simultaneously. The primers of GAB2 associated binding protein 2 (GAB2) were as follows, forward: aggaagagTAG ATG GGT GGG TCC AT; reverse: cagtaatagggagaaggctACA  ACC TCC CCT CCA ACC AA, which results 354 bp fragments. The resulting DNA fragments were identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, and EpiTYPER (Agena Bioscience, San Diego, CA, USA) was used for the quantification of CpG methylation level.

Quantitative real time PCR analysis (qRT-PCR)
Total RNA in liver and adipose was extracted using TRIzol reagent (#15956-026, Invitrogen, USA) according to the manufacturer’s protocol. 2 µg total RNA was used for cDNA synthesis using the Hifair® II 1st Strand cDNA Synthesis Kit (#HB200724, YEASON, China). Total cDNA was amplified using SYBR Premix Ex Taq (Tli RNaseH Plus) (#RR420A, TaKaRa, Japan). PCRs were performed using a LightCycler (Roche Diagnostics, USA). Samples were analyzed in triplicate. Gene expression was expressed as 2(−ΔΔCt) and normalized to the housekeeping gene β-Actin, forward: CCCAGCACAATGAGACTCAAGATCAT; reverse: ATCTGCTGAGGTGGAGCAGCG. The sequences of the primers used were as follows: GAB2 (forward: ATAGGCAGAGTGGGTCCAT; reverse: TTGCCACATGGGAGATCCAC).

Statistical analysis
Clinical data in human was presented as mean ± standard deviation or standard error. Paired t test and independent samples t test were adopted for the inter- and intra-group comparison. One-way ANOVA was used for comparison among multiple groups. Least significant difference (LSD) test [36] was used for pairwise comparisons between groups under the assumption that the variance was uniform. Non-normally distributed data was analyzed by converting log to normal distributed data, and non-parametric testing, i.e., Mann–Whitney U and Kruskal–Wallis H test, was used for data that cannot be converted into normal distributed data. Correlation between methylation of CpG units and serum traits or mRNA expression were calculated using Spearman correlation analysis. P < 0.05 was considered statistically significant.

Results
Human trial
Anthropometric and clinical measurement
General characteristics of the study participants are shown in Table 1. After 6-month intervention, HFC (p = 0.004, p = 0.005 and p = 0.012) and total FM (p = 0.001, p = 0.022 and p = 0.034) were significantly lower, while VO2max (p = 0.041, p = 0.002 and p = 0.001) was higher in the Ex, LCD and ELCD groups. Weight (p < 0.001 and p = 0.012), BMI (p = 0.001 and p = 0.015) and android FM (p = 0.034 and p = 0.001) were lower both in Ex and ELCD group, while VAT (p = 0.004 and p = 0.029) decreased in Ex and LCD group. The Ex group had decreased level of gynoid FM, SAT, fasting and 2 h glucose, TG and cholesterol (p = 0.001, p = 0.011, p = 0.036, p = 0.019, p = 0.021 and p = 0.040). By contrast, the No group had increased BMI, HFC, total body and android FM (p = 0.045, p = 0.004, p = 0.003 and p = 0.035).

Differential methylation of global and individual CpG loci
We firstly examined DNA methylation difference among the 865,918 analyzed CpGs in peripheral blood in response to Ex, LCD and ELCD intervention (Fig. 1) and estimating overlap in control group. After comparing the methylation of individual CpGs between baseline and follow-up, 100118, 268582, 270663 and 259249 differentially methylated CpGs (q < 0.05) were identified in Ex, LCD and ELCD and No groups, respectively. A pattern of methylation across the genome with the least methylation in promoter regions and the most
Table 1  Clinical characteristics of study participants (n = 32) with DNA methylation data both before (baseline) and after the intervention

| Variables                  | Ex (n = 8)     | LCD (n = 8)    | ELCD (n = 9)   | No (n = 7)     | Within Groups (p value) |
|----------------------------|----------------|----------------|----------------|----------------|-------------------------|
|                            | Baseline       | Intervention   | Baseline       | Intervention   | Baseline       | Intervention   | Ex Diet | Ex + Diet | No         |            |
| HFC (%)                    | 236 (11.0)     | 11.0 (5.5)     | 17.2 (13.6)    | 11.0 (13.2)    | 192 (11.1)    | 6.7 (4.1)     | 10.3 (5.6)    | 15.4 (7.3)  | 0.004      | 0.005      | 0.012      | 0.004      |
| Weight (kg)                | 684 (100)      | 64.8 (10.8)    | 65.1 (8.8)     | 63.7 (9.1)     | 659 (6.2)     | 64.2 (6.2)    | 65.2 (13.4)   | 66.2 (13.9) | < 0.001    | 0.098      | 0.012      | 0.059      |
| BMI (kg/m²)                | 275 (3.0)      | 26.1 (3.4)     | 26.6 (3.8)     | 26.0 (4.0)     | 258 (2.2)     | 25.1 (2.3)    | 25.9 (3.7)    | 26.2 (3.9)  | 0.001      | 0.084      | 0.015      | 0.045      |
| LM (kg)                    | 379 (5.6)      | 37.3 (5.6)     | 38.1 (4.8)     | 37.9 (4.9)     | 382 (3.0)     | 37.5 (3.5)    | 39.3 (8.0)    | 38.6 (8.4)  | 0.092      | 0.535      | 0.113      | 0.058      |
| FM Android (kg)            | 284 (6.1)      | 25.5 (5.8)     | 24.9 (4.0)     | 23.8 (4.4)     | 257 (4.2)     | 24.7 (4.5)    | 24.6 (6.9)    | 26.2 (7.1)  | 0.002      | 0.022      | 0.034      | 0.003      |
| FM Gynoid (kg)             | 284 (0.6)      | 2.56 (0.8)     | 2.42 (0.5)     | 2.24 (0.4)     | 2.43 (0.5)    | 2.25 (0.4)    | 2.41 (0.8)    | 2.59 (0.7)  | 0.034      | 0.059      | 0.001      | 0.035      |
| VAT (kg)                   | 365 (0.8)      | 3.47 (0.7)     | 3.32 (0.9)     | 3.18 (0.8)     | 3.48 (0.8)    | 3.35 (0.9)    | 3.27 (0.8)    | 3.46 (0.8)  | 0.001      | 0.070      | 0.186      | 0.105      |
| SAT (kg)                   | 183 (0.6)      | 1.45 (0.6)     | 1.44 (0.6)     | 1.20 (0.6)     | 1.47 (0.7)    | 1.31 (0.6)    | 1.62 (0.8)    | 1.70 (0.8)  | 0.004      | 0.029      | 0.058      | 0.413      |
| Glucose fasting (mmol/L)   | 573 (0.5)      | 5.26 (0.6)     | 5.48 (0.9)     | 5.58 (0.8)     | 5.50 (0.7)    | 5.48 (0.3)    | 5.97 (0.5)    | 6.11 (0.7)  | 0.036      | 0.737      | 0.939      | 0.392      |
| Glucose 2-h (mmol/L)       | 9.34 (2.2)     | 6.63 (1.3)     | 8.16 (1.5)     | 6.54 (3.0)     | 8.21 (1.3)    | 6.98 (2.1)    | 8.13 (1.1)    | 8.60 (2.7)  | 0.019      | 0.245      | 0.076      | 0.637      |
| Insulin fasting (µIU/mL)   | 259 (15.4)     | 18.4 (10.6)    | 14.3 (11.5)    | 13.9 (8.3)     | 20.2 (8.1)    | 15.9 (4.5)    | 16.4 (10.8)   | 16.4 (12.0) | 0.154      | 0.843      | 0.067      | 0.997      |
| HBA1c (%)                  | 6.19 (0.3)     | 6.07 (0.3)     | 6.07 (0.3)     | 6.13 (0.2)     | 5.83 (0.5)    | 5.7 (0.5)     | 6.52 (0.2)    | 6.45 (0.4)  | 0.280      | 0.673      | 0.354      | 0.666      |
| Triglyceride (mmol/L)      | 2.05 (1.8)     | 1.40 (1.2)     | 1.76 (0.8)     | 1.51 (0.5)     | 2.62 (1.1)    | 2.14 (1.1)    | 2.01 (1.0)    | 2.24 (1.3)  | 0.021      | 0.332      | 0.195      | 0.555      |
| Cholesterol (mmol/L)       | 6.00 (0.7)     | 5.19 (0.9)     | 5.12 (0.9)     | 4.85 (0.6)     | 6.19 (1.2)    | 5.18 (0.6)    | 6.06 (0.9)    | 6.22 (0.7)  | 0.040      | 0.456      | 0.071      | 0.752      |
| ALT (U/L)                  | 240 (11.7)     | 163 (5.6)      | 22.6 (16.0)    | 18.6 (10.3)    | 24.6 (11.7)   | 22.6 (9.9)    | 18.7 (8.5)    | 30.7 (15.3) | 0.232      | 0.533      | 0.511      | 0.116      |
| AST (U/L)                  | 275 (4.2)      | 195 (7.1)      | 24.4 (12.4)    | 23.5 (9.8)     | 24.7 (6.7)    | 23.0 (7.5)    | 24.6 (7.2)    | 28.4 (7.0)  | 0.081      | 0.887      | 0.663      | 0.496      |
| VO₂max (mL/min/kg)         | 137 (4.9)      | 18.0 (3.9)     | 16.6 (3.9)     | 19.8 (3.1)     | 159 (4.5)     | 25.0 (2.9)    | 17.9 (4.2)    | 21.1 (5.3)  | 0.041      | 0.002      | < 0.001    | 0.151      |

Variables are presented as mean (SD). P values are based on a paired t test.

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; ELCD: Exercise plus low carbohydrate diet intervention; Ex: Exercise intervention; F Mandroid: Android fat mass; FMygynoid: Gynoid fat mass; FMwb: Total body fat mass; HBA1c: Glycated hemoglobin; HFC: Hepatic fat content; LCD: Low carbohydrate diet; LM: Total body lean mass; No: No intervention; SAT: Abdominal subcutaneous fat content; VAT: Abdominal visceral fat content; VO₂max: Maximal oxygen uptake.
methylation in the ExonBnd and 3 prime untranslated region (3’UTR) was observed. Significantly lower methylation levels were observed in pre-intervention than post-intervention for all gene regions except 3’UTR in LCD and ELCD groups (p < 0.05). Furthermore, the least methylation in CpG island and most methylation in the shelves and open sea were found, which was significantly more methylated at post-intervention than pre-intervention except for the open sea region in LCD and ELCD groups (p < 0.05) (Fig. 2).

**3D genome territorial and k-means clustering**

We further selected 430, 2807 and 1648 differentially methylated CpGs within promoters, corresponding to 404, 2661 and 1575 (q < 0.01, |Δβ| ≥ 0.1) genes in Ex, LCD and ELCD group, respectively, after excluding the overlap CpGs with No group. Then, the above differentially methylated genes were assigned 3D genome coordinates according to the chromosome number and TSS using our 3D modeling methods [33]. These differentially methylated genes with 3D genome information were separated into 100 clusters by K-means clustering algorithm (optimal cluster numbers were pre-investigated).

**Differential methylation at the pathway level**

To better understand the biological function of the differentially methylated genes, KEGG enrichment analysis was conducted in three intervention groups (Additional file 2) and the relevant pathways, i.e., lipid metabolism (e.g., fat digestion and absorption, fatty acid degradation), carbohydrate metabolism (e.g., glycolysis, fructose and mannose metabolism), inflammation (e.g., IL-17 signaling pathway and TNF signaling pathway) and key signaling pathways (e.g., PPAR signaling pathway and TGF-beta signaling pathway) were identified.

To visualize the gene–gene interaction, graphs with clusters being marked according to 3D genome coordinates were displayed (Fig. 3). And we observed that genes, e.g., GAB2 and HRas proto-oncogene (HRAS), insulin (INS) and CD81, which were included in the pathways related to lipid metabolism and inflammation were belonged to cluster 63 after LCD intervention. Genes including GAB2, HRAS, P21 activated kinase 1 (PAK1) and lactate dehydrogenase A (LDHA), that are related to lipid and carbohydrate metabolism, were assigned to cluster 67 after ELCD intervention. Notably, both GAB2 were hypomethylated and HRAS was hypermethylated in response to LCD and ELCD intervention (Table 2).

From the aspect of gene structure and gene function by 3D genome information and KEGG analysis respectively, we observed that GAB2 and HRAS were assigned to the same cluster after LCD and ELCD intervention respectively (Fig. 3), and involved in phospholipase D signaling pathway (Additional file 2), which are highly related to lipid metabolism [37]. Combine this finding with GAB2 being regarded as a candidate gene regulating hepatic steatosis and steatohepatitis [38, 39], we decided to firstly evaluate if GAB2 belongs to genes that showing decreased DNA methylation in the promoter region coupled with increased mRNA expression in liver and adipose of NASH after LFD or ELFD intervention; animal experiment followed by human trial was thus carried on.

### Animal experiment

**Basic traits in NASH mice before and after intervention**

After 4 weeks of MCD diet feeding, the histology of liver was examined to check whether NASH model was successful by HE staining (Additional file 3). Then NASH mice were assigned to intervene for 4 weeks. And liver histological characteristics were stained with HE (Additional file 4) to check whether lifestyle intervention decreases the triglyceride accumulation and improves the inflammation symptom in NASH. Furthermore, oil red O staining was also used to detect the lipid change in HFD, EHFD, LFD, ELFD and MCD groups (Additional file 5). And the reduced vesicular degeneration was seen after LFD and ELFD intervention with both HE and oil red O staining.

Basic traits were shown in the additional files (Additional files 6, 7, 8). Weight of all the intervention groups i.e., HFD, EH, LFD and ELFD were much higher than MCD group. There was a significant increase in ALT and AST level, but decrease in total cholesterol and triglyceride of MCD group compared with intervention groups. The cholesterol level in HFD was much higher.
Fig. 2 Location of analyzed CpG sites and global DNA methylation in NAFLD after intervention. A, B, C and D indicate Ex, LCD, ELCD and No groups, respectively. Pre and Post indicate samples are taken before and after intervention, respectively. Ex: exercise intervention; ELCD: exercise plus low carbohydrate diet; LCD: low carbohydrate diet; No: no intervention. *P < 0.05
than EHFD, but triglyceride was significantly lower in HFD than EHFD (p < 0.05). No significant differences in cholesterol and triglyceride were found in LFD and ELFD groups.

To check diet effect and exercise plus diet effect on DNA methylation of GAB2 in NASH, DNA methylation profiling by EpiTyper MassARRAY and relative mRNA expression profiling by qRT-PCR were conducted for MCD, HFD, LFD and ELFD groups.

**Diet effect on DNA methylation and mRNA expression of GAB2 in liver and adipose of NASH mice**

In liver, methylation level of CpG_1.2 within GAB2 were much lower in MCD than LFD and HFD groups (p = 0.043) (Table 3). The relative mRNA expression of
GAB2 in MCD group was higher than LFD and HFD (p < 0.05) (Fig. 4).

In adipose, CpG_6.7 and average methylation level of GAB2 were much higher in LFD group than MCD and HFD groups (p = 0.048) (Table 3). While there was no significant difference in relative mRNA expression of GAB2 among the three groups (Fig. 4).

**Exercise plus diet effect on DNA methylation and mRNA expression of GAB2 in liver and adipose of NASH mice**

In liver, a significant increase in methylation level of CpG_18.19 within GAB2 of ELFD group was found when comparing with MCD group (p = 0.029) (Table 3). But there was no significant difference in relative mRNA level of GAB2 between these two groups (Fig. 4).

In adipose, average methylation level and seven specific CpG units including CpG_10.11.12, CpG_13.14.15, CpG_18.19, CpG_25.26.27.28, CpG_30, CpG_31, CpG_33 of GAB2 showed significantly increase in ELFD group than MCD group (p < 0.05), except CpG_6.7 (Table 3). And the expression of GAB2 in EL group was significantly lower than MCD group (p = 0.045) (Fig. 4).

---

**Table 3**  
GAB2 methylation values (%) for each CpG unit among four groups in liver and adipose tissues of mice

| CpGs       | Liver (Methylation%) | MCD | LFD | HFD | ELFD | P1   | P2   | Adipose (Methylation%) | MCD | LFD | HFD | ELFD | P3   | P4   |
|------------|----------------------|-----|-----|-----|------|------|------|-------------------------|-----|-----|-----|------|------|------|
| CpG_1.2    | 0.00                 | 3.80| 4.00| 29.50| 0.043| 0.114| 1.71 | 1.00                    | 1.83| 1.86| 0.327| 0.620|      |      |
| CpG_3      | 0.00                 | 0.40| 5.33| 1.00 | 0.075| 0.686| 2.29 | 3.67                    | 0.33| 2.57| 0.288| 1.000|      |      |
| CpG_5      | 8.00                 | 4.20| 10.17| 0.00| 0.459| 0.114| 0.43 | 1.19                    | 5.83| 1.00| 0.754| 0.318|      |      |
| CpG_6.7    | 9.25                 | 14.00| 15.00| 4.00| 0.522| 0.400| 8.71 | 18.33                   | 5.67| 2.57| 0.044| 0.001|      |      |
| CpG_8      | 2.25                 | 3.25| 5.67| 31.50| 0.812| 0.200| 1.14 | 1.88                    | 4.33| 1.43| 0.360| 1.000|      |      |
| CpG_9      | 6.25                 | 8.00| 0.83| 6.00 | 0.054| 0.686| 1.14 | 4.11                    | 2.17| 5.00| 0.216| 0.073|      |      |
| CpG_10.11.12| 3.75             | 9.00| 6.17| 8.00 | 0.498| 0.629| 3.14 | 5.33                    | 3.00| 8.43| 0.184| 0.002|      |      |
| CpG_13.14.15| 2.50             | 3.80| 2.67| 18.25| 0.400| 0.114| 2.29 | 3.11                    | 2.33| 6.29| 0.842| 0.001|      |      |
| CpG_16.17  | 3.00                 | 3.00| 3.00| 20.75| 0.608| 0.057| 3.43 | 3.44                    | 2.33| 6.86| 0.303| 0.053|      |      |
| CpG_18.19  | 2.00                 | 2.60| 3.50| 15.75| 0.427| 0.029| 2.00 | 1.44                    | 2.17| 6.57| 0.203| 0.001|      |      |
| CpG_20.21  | 3.75                 | 2.60| 9.83| 10.00| 0.342| 0.200| 0.71 | 3.67                    | 7.67| 1.86| 0.598| 0.073|      |      |
| CpG_23.24  | 3.00                 | 4.00| 3.33| 6.25 | 0.788| 0.343| 3.29 | 3.78                    | 2.83| 4.57| 0.466| 0.002|      |      |
| CpG_25.26.27.28| 7.25             | 10.40| 10.17| 13.00| 0.134| 0.200| 8.86 | 10.33                   | 10.00| 11.29| 0.359| 0.017|      |      |
| CpG_30     | 2.25                 | 3.00| 3.50| 6.75 | 0.918| 0.343| 2.57 | 2.67                    | 1.83| 9.86| 0.155| 0.001|      |      |
| CpG_31     | 5.25                 | 1.60| 5.17| 3.50 | 0.308| 0.486| 2.71 | 4.78                    | 2.86| 10.29| 0.670| 0.001|      |      |
| CpG_33     | 0.75                 | 1.20| 2.33| 0.50 | 0.386| 0.486| 1.43 | 1.56                    | 0.83| 3.57| 0.225| 0.026|      |      |
| Average CpG| 3.70                 | 4.68| 5.69| 12.13| 0.513| 0.057| 2.87 | 4.59                    | 3.03| 5.25| 0.048| 0.001|      |      |

P1 and P3 indicate p value among MCD, LFD and HFD in liver and adipose, respectively. P2 and P4 indicate p value between MCD and ELFD in liver and adipose, respectively.

CpGs: cytosine-guanine dinucleotides; GAB2: GRB2 associated binding protein 2; ELFD: exercise plus low fat diet; HFD: high fat diet; LFD: low fat diet; MCD: methionine choline deficient.

---

**Fig. 4** Relative mRNA expression level of GAB2 in mice liver and adipose tissue. A and B indicate relative mRNA expression levels of GAB2 among MCD, LFD and HFD groups in liver and adipose, respectively. P values in A and B are based on one way ANOVA. C and D indicate relative mRNA expression levels of GAB2 between MCD and ELFD groups in liver and adipose, respectively. P values in C and D are based on independent samples T test. *P < 0.05; **P < 0.01; ns: no significance.
**Correlation between methylation of CpG units and serum traits in NASH mice after intervention**

In liver, methylation level of CpG_18.19 was positively correlated with ALT and AST, but negatively correlated with cholesterol and triglyceride; methylation level of CpG_5 was positively correlated with ALT and AST, but negatively correlated with cholesterol; methylation level of CpG_1.2 and CpG_25.26.27.28 were both positively correlated with cholesterol (p < 0.05) (Table 4).

In adipose, negative relationship between average methylation of CpG units and specific methylation of CpG units (i.e., CpG_9, CpG_10.11.12, CpG_13.14.15, CpG_16.17, CpG_18.19, CpG_25.26.27.28, CpG_30, CpG_31 and CpG_33) and ALT and AST were observed; average methylation level of CpG and specific CpG units (i.e., CpG_10.11.12, CpG_13.14.15, CpG_18.19, CpG_20.21, CpG_30 and CpG_31) was positively related to cholesterol, of these, CpG_10.11.12, CpG_13.14.15, CpG_18.19 and CpG_31 were also positively correlated with triglyceride. Methylation of CpG_10.11.12 was negatively correlated with mRNA expression of GAB2 (p < 0.05) (Table 4).

**Discussion**

This study highlighted the respective and combined effects of exercise and diet intervention on the blood DNA methylation in NAFLD, and evaluated whether these interventions protected liver and adipose against NASH via DNA methylation. Our results revealed that (1) lifestyle intervention can trigger genome-wide differential DNA methylation changes in human NAFLD; (2) both LCD and ELCD intervention on human NAFLD can induce same DNA methylation alterations at critical genes in blood, e.g., GAB2, which was also validated in liver and adipose of NASH mice after LFD and ELFD intervention; (3) methylation of CpG units (i.e., CpG_10.11.12) inversely correlated with mRNA expression GAB2 in adipose tissue of NASH mice after ELFD intervention.

The NAFLD is a disorder that extends from simple hepatic steatosis to NASH, which can be modeled by feeding MCD diet in mice to induce the elevation of aminotransferase and concurrent changes of hepatic histology with steatosis, hepatocyte ballooning and inflammation, and fibrosis [40, 41], and these histological changes are similar with those seen in human NASH. Notably, this complex disease cannot be solely explained by genetic and epigenetic factors. DNA methylation, which affects gene expression without changing the nucleotide sequence, acts as underling mechanistic modification to impact on the disease [42]. Moreover, DNA methylation can be affected by environmental factors such as exercise and diet, and differs significantly among skeletal muscle, adipose and liver tissues [43, 44]. Considering the applicability and effectiveness, LCD (40% fat and 40% carbohydrate) was chosen to improve NAFLD in...
human [45, 46], and LFD (10% fat and 70% carbohydrate) was used in NASH mice in the present study. Increased DNA methylation level of CpG island within GAB2 in adipose of mice NASH after LFD and ELFD intervention was observed, which was in line with the result from NAFLD human after LCD and ELCD intervention, as a decrease in DNA methylation of the promoter within GAB2 has shown. These findings strongly suggest that DNA methylation modification plays a critical role in human NAFLD and mice NASH fed a MCD diet responding to the lifestyle intervention.

To explore the optimal lifestyle intervention for NAFLD and NASH via influence on DNA methylation, respective and concurrent exercise and diet intervention were both applied in this study. The results revealed the mRNA expression of GAB2 was repressed corresponding to the upregulated DNA methylation in NASH after ELFD intervention. Therefore, ELFD intervention was the preferred effective strategy for the treatment of NASH in this study. This discovery is in line with the report of Eckard et al. [47] that the combined intervention with exercise and diet improved liver histology, rather than the sole exercise intervention, and moreover, Goodpaster et al. [48] found that there was an addition of exercise on the reduction of HFC and waist circumstance in the obese. In contrast, Gepner et al. [49] showed that no additive effects of moderate physical activity upon Mediterranean diet and LFD intervention on HFC of NAFLD; Andersson et al. [50] reported that effects on HFC was independent of exercise or exercise plus diet interaction. More research is needed to explain these inconsistencies and elucidate the role of exercise or exercise and diet intervention in NAFLD, especially focusing on the DNA methylation mechanism behind these conditions, as this epigenetic modification is dynamically regulated by environmental factors and subsequently affect diseases.

Considering that CpG sites within the promoter region of human GAB2 gene were reported to be hypomethylated in the blood of NAFLD patients in response to LCD and ELCD, and GAB2 deletion prevented hepatic steatosis induced by HFD and steatohepatitis induced by MCD diet in mice [38], in this study, GAB2 in the LFD vs. MCD or ELFD vs. MCD comparison was selected to examine its DNA methylation and gene expression in liver and adipose of NASH mice after LFD or ELFD intervention. Regarding the function of GAB2, Chen et al. [38] showed that GAB2 could promote lipid accumulation in HepG2 cells in vitro, and Wang et al. [39] found that increase of GAB2 expression in adipose was induced by HFD in mice. GAB2 plays important roles in differentiation, proliferation and cell migration in multiple cells [51] by recruiting factors, e.g., Ras, p85 and Shp2 [52, 53]. Although no significant difference in GAB2 mRNA expression in liver between ELFD and MCD groups was found in this study, mRNA expression level in MCD group was much higher than ELFD, in accord with DNA methylation in MCD group was significantly lower than ELFD in adipose. This suggests that ELFD could modulate GAB2 methylation and expression status of adipose in NASH.

Liver dysfunction was assessed by serum measurements of liver enzymes ALT and AST. The elevation of these enzymes reflects liver damage caused by either cell death or a transient leak [54, 55]. A positive correlation between average methylation of GAB2 in adipose and ALT or AST was demonstrated, and both ALT and AST level were much lower after LFD and ELFD intervention in this study, indicating a role of adipose tissue GAB2 in liver damage. Nevertheless, only methylation of CpG_5 and CpG_18.19 of GAB2 was associated with ALT and AST in liver, which might result from the tissue specific changes between liver and adipose in NASH after LFD and ELFD intervention, as NASH and these lifestyle interventions can make it difficult to not only identify the pathological or adaptive role of DNA methylation events but also to recognize the primary benefits that triggers secondary or systemic changes of these stimulation. In addition, Nano et al. [56] has shown that ALT, gamma-glutamyl transferase and triglyceride were associated with methylation of SLC7A11 in blood, which was reported to be linked to adiposity [57]. These findings gave indirect evidence that DNA methylation could be a contributor to the development or prevention of liver diseases.

It is well known that most CpG islands are not methylated when located at TSS, and methylation of CG island at TSS is associated with silenced gene expression [31]. Most gene bodies have poor CpG sites, but can still be extensively methylated, making the role of gene body methylation in mammal very intriguing. It has been reported that there is a positive correlation between gene body methylation and active transcription in animal genomes [58], and that methylation blocks the start of transcription rather than elongation. Our results were consistent with above findings which showed that methylation of CpG island of GAB2 was upregulated via ELFD in NASH mice, and mRNA expression of GAB2 was downregulated. It is thus conjectured that methylation of CpG island in GAB2 might interrupt the start of transcription activity and thus inhibit the mRNA expression of GAB2.

This study focuses on two main contributions. Firstly, a quantitative methylation analysis via Sequenom’s MassARRAY system was employed to validate the DNA methylation change of GAB2, which was screened with Infinium Methylation EPIC Bead Chip assay on a genome wide scale in this study to increase the reliability.
Secondly, respective and combined exercise and diet intervention were conducted as strategies to combat NAFLD and NASH, and the importance of concurrent intervention (i.e., ELFD) which effectively affected DNA methylation and mRNA expression of GAB2 in adipose of NASH mice was revealed. Some limitations of this study include: firstly, the human sample size is relatively small, and the result was not replicated in an independent population, and more studies with larger sample sizes are needed to confirm our findings; secondly, because of the lack of RNA sample, this study may not provide the information of expression data of GAB2 in human; thirdly, only CpG sites of promoters in human trial were included for the screening of differentially methylated genes, and methylation in other gene regions may also be affected by the exposure of lifestyle intervention in NAFLD; lastly, DNA methylation associations with NAFLD in response to lifestyle intervention could be confounded by different cell types in blood, and adjusting for changes in cell composition in future studies is needed. However, the validation of differentially methylated gene GAB2 in liver and adipose tissue in NASH mice may be a better substitute for replication in another population because epigenetic modifications are rather tissue specific, and furthermore verified the modification of DNA methylation of GAB2 may also be a target for the treatment of NASH, not only NAFLD.

Conclusions
We highlighted the susceptibility of DNA methylation in GAB2 to ELFD intervention, through which exercise and diet can protect against the progression of NAFLD and NASH on the genome level. We also demonstrated that the DNA methylation variation in blood could mirror epigenetic signatures in target tissues of important biological function, i.e., liver and adipose tissue. We also clarified that the association between DNA methylation of CpG units in GAB2 and ALT, AST, total cholesterol and triglyceride, which was a step towards understanding the epigenetic programming of the disease development and identifying new epigenetic molecular targets to avert potential NAFLD, NASH and relevant liver diseases consequences.

Abbreviations
ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; Ex: Exercise; BCAT1: Branched-chain amino-acid transaminase 1; CASP1: Caspase 1; EHFD: Exercise plus high fat diet; ELFD: Exercise plus low fat diet; ELCD: Exercise plus low carbohydrate diet; FM: Fat mass; FGFR2: Fibroblast growth factor receptor 2; GAB2: GRB2 Associated binding protein 2; HE: Haematoxylin and eosin; HFC: Hepatic fat content; HFD: High fat diet; HRAS: Hras Proto-oncogene, 1NS: Insulin; KEGG: Kyoto encyclopedia of genes and genomes; LDHA: Lactate dehydrogenase A; LCD: Low carbohydrate diet; LFD: Low fat diet; LM: Lean mass; VO2max: Maximum oxygen uptake; MCS: Methionine choline sufficient; MCD: Methionine choline sufficient diet; MCSM: Methionine choline sufficient diet (4 weeks); MCD: Methionine choline sufficient diet (8 weeks); MCSC: Methionine choline sufficient diet (4 weeks); MCD: Methionine choline sufficient diet (8 weeks); ELCD, exercise plus low carbohydrate diet; LCD, low carbohydrate diet; NAFLD, nonalcoholic fatty liver disease; NASH: Nonalcoholic steatohepatitis; PAK1: P21 Activated kinase 1; PPARα and PPARγ: Peroxisome proliferator-activated receptor-alpha and -gamma; PDGF: Platelet-derived growth factor subunit A; qRT-PCR: Quantitative reverse transcription polymerase chain reaction analysis; SPF: Specific pathogen free; TSS: Transcription start site; SAT: Subcutaneous adipose tissue; UTR: Untranslated region; VAT: Visceral adipose tissue.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13578-021-00701-6.

Additional file 1: Fig. S1. Flow chart of exercise and diet intervention on DNA methylation of NAFLD in human. 1Ex, exercise intervention; ELCD, exercise plus low carbohydrate diet; LCD, low carbohydrate diet; NAFLD, nonalcoholic fatty liver disease; No, no intervention.

Additional file 2: Table S1. KEGG pathway analysis in NAFLD after lifestyle intervention (q < 0.05).

Additional file 3: Fig. S2. Histological assessment of liver in between MCD and MCS groups. 1MCD, methionine choline deficiency diet (4 weeks); MCS, methionine choline sufficient diet (4 weeks). Scale bars = 100 μm.

Additional file 4: Fig. S3. Histological assessment of liver in NASH mice after intervention stained with HE. 1Intervention groups: EHFD, exercise plus high fat diet; ELFD, exercise plus low fat diet; HE, haematoxylin and eosin; HFD, high fat diet; LFD, low fat diet; MCSM, methionine choline sufficient diet (4 weeks). None intervention groups: MCD, methionine choline deficiency diet (8 weeks); MCSC, methionine choline sufficient diet (8 weeks). Scale bars = 100 μm.

Additional file 5: Fig. S4. Histological assessment of liver in NASH mice after intervention stained with oil red O. 1Intervention groups: EHFD, exercise plus high fat diet; ELFD, exercise plus low fat diet; HFD, high fat diet; LFD, low fat diet; intervention groups: MCD, methionine choline deficiency diet (8 weeks). Scale bars = 100 μm.

Additional file 6: Table S2. Clinical traits of NASH mice after intervention. 1Intervention groups: EHFD, exercise plus high fat diet; ELFD, exercise plus low fat diet; HFD, high fat diet; LFD, low fat diet; MCD, methionine choline deficiency diet (8 weeks). Scale bars = 100 μm.

Additional file 7: Fig. S5. Weight comparison among different groups in NASH mice. 1Intervention groups: EHFD, exercise plus high fat diet; ELFD, exercise plus low fat diet; HFD, high fat diet; LFD, low fat diet; MCSM, methionine choline sufficient diet (4 weeks). None intervention groups: MCD, methionine choline deficiency diet (8 weeks); MCSC, methionine choline sufficient diet (8 weeks).

Additional file 8: Fig. S6. Clinical traits comparison among different groups in NASH mice. 1Intervention groups: EHFD, exercise plus high fat diet; ELFD, exercise plus low fat diet; HFD, high fat diet; LFD, low fat diet; MCD, methionine choline deficiency diet (8 weeks); MCSC, methionine choline sufficient diet (8 weeks).

Acknowledgements
We would like to thank the participants in this study.

Authors’ contributions
The authors’ responsibilities were as follows. GH, YS, and SL designed research; NW, FY, SY, FY, and FY conducted research; NW, DR, LL, YB, ZG, LJ, KH, XY, MF, and KS analyzed and interpreted data; NW wrote the paper; SY, GH, SL, BL, RW, XW, QL and XW reviewed the manuscript critically. None of the authors reported a conflict of interest related to the study. All authors read and approved the final manuscript.
Funding
This project is supported by the National Key Research and Development Program (2016YFC0906400), Innovation Funding in Shanghai (20JC141860, 18JC1413100), the National Nature Science Foundation of China (82071262, 81671526), Natural Science Foundation of Shanghai (20ZR1427200, 20151101900), Shanghai Municipal Science and Technology Major Project (2017SHZDZX01), the Shanghai Leading Academic Discipline Project (B205).

Availability of data and materials
Not applicable.

Declarations

Ethics approval and consent to participate
The study was approved by the Ethics Committee of Shanghai Institute of Nutrition (0601.2013, ref. 2013-003) and registered in the International Standard Randomized Controlled Trial Number Register (ISRCTN42622771). A written informed consent was obtained from each subject. The animal studies and protocols were approved by the Experimental Animal Ethics Committee of Shanghai University of Traditional Chinese Medicine.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Shanghai Jiao Tong University, 1954 Huashan Road, Shanghai 200030, China. 2 Shanghai Innovation Center of Traditional Chinese Medicine Health Service; Shanghai University of Traditional Chinese Medicine, Shanghai, China. 3 Shanghai Key Laboratory of Psychotic Disorders, and Brain Science and Technology Research Center, Shanghai Jiao Tong University, Shanghai, China. 4 Exercise Translational Medicine Center, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China.

Received: 21 May 2021 Accepted: 25 October 2021
Published online: 04 November 2021

References
1. Hossain IA, Akter S, Bhuiyan FR, Shah MR, Rahman MK, Ali L. Subclinical inflammation in relation to insulin resistance in prediabetic subjects with nonalcoholic fatty liver disease. BMC Res Notes. 2016;9:266.

2. Zelber-Sagi S, Lotan R, Shibolet O, Webb M, Buch A, Nitzan-Kaluski D, et al. Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up. Liver Int. 2013;33(9):1406–12.

3. Hashizume H, Sato K, Yamazaki Y, Horiguchi N, Kakizaki S, Mori M. A prospective study of long-term outcomes in female patients with nonalcoholic steatohepatitis using age- and body mass index-matched cohorts. Acta Med Okayama. 2013;67(1):45–53.

4. Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic steatohepatitis: current concepts in epidemiology and management. Expert Rev Gastroenterol Hepatol. 2011;5(3):912–8.

5. Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, et al. One-year intensive nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol. 2005;100(5):1072–81.

6. Promrat K, Kleinier DE, Niemeyer HM, Jackkony F, Eerens M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51(1):121–9.

7. Cheng S, Ge J, Zhao C, Le S, Yang Y, Ke D, et al. Effect of aerobic exercise and diet on liver fat in pre-diabetic patients with non-alcoholic fatty-liver-disease: a randomized controlled trial. Sci Rep. 2017;7(1):15952.

8. Eslam M, Valent L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol. 2018;68(2):268–79.

9. Gallego-Duran R, Romero-Gomez M. Epigenetic mechanisms in non-alcoholic fatty liver disease: an emerging field. World J Hepatol. 2015;7(24):2497–502.

10. Gluckman PD, Hanson MA, Buklijas T, Low FM, Beedle AS. Epigenetic mechanisms that underpin metabolic and cardiovascular diseases. Nat Rev Endocrinol. 2009;5(7):401–8.

11. Wu J, Zhang R, Shen F, Yang R, Zhou D, Cao H, et al. Altered DNA methylation sites in peripheral blood leukocytes from patients with simple steatosis and nonalcoholic steatohepatitis (NASH). Med Sci Monit. 2018;24:6946–67.

12. Lim U, Song MA. Dietary and lifestyle factors of DNA methylation. Methotrexate Mol Biol. 2012;863:359–76.

13. Zhou D, Hiday RA, Schafer MJ, White TA, Liu C, Choi JH, et al. High fat diet and exercise lead to a disrupted and pathogenic DNA methylation in mouse liver. Epigenetics. 2017;12(1):55–69.

14. Yoon A, Tammen SA, Park S, Han SN, Choi SW. Genome-wide hepatic DNA methylation changes in high-fat diet-induced obese mice. Nutr Res Pract. 2011;7(2):105–13.

15. Yaskolka Meir A, Keller M, Muller L, Bernhart SH, Tsaban G, Zelicha H, et al. Effects of lifestyle interventions on epigenetic signatures of liver fat: central randomized controlled trial. Liver Int. 2021;41(9):2101–11.

16. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat Rev Genet. 2018;19(6):371–84.

17. Liu WY, Lu DJ, Du XM, Sun JQ, Ge J, Wang RW, et al. Effect of aerobic exercise and low carbohydrate diet on pre-diabetic non-alcoholic fatty liver disease in postmenopausal women and middle aged men—the role of gut microbiota composition: study protocol for the AELC randomized controlled trial. BMC Public Health. 2014;14:48.

18. Borra RJ, Solis D, Dean K, Lautamaki R, Nuutila P, Ketola M, et al. Nonalcoholic fatty liver disease: rapid evaluation of liver fat content with in-phase and out-of-phase MR imaging. Radiology. 2009;250(1):30–6.

19. Scheidegger O, Wingeier K, Stefan D, Graveron-Demilly D, van Ormondt D, Wisst R, et al. Optimized quantitative magnetic resonance spectroscopy for clinical routine. Magn Reson Med. 2013;70(1):25–32.

20. Abate N, Garg A, Coleman R, Grundy SM, Peshock RM. Prediction of total subcutaneous abdominal, intraperitoneal, and retroperitoneal adipose tissue masses in men by a single axial magnetic resonance imaging slice. Am J Clin Nutr. 1997;65(2):403–8.

21. Pidsley R, Zotenko E, Peters TJ, Lawrence MG, Rixbriger GP, Molloy P, et al. Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling. Genome Biol. 2016;17(1):208.

22. Bibikova M, Barnes B, Tsan C, Ho V, Klotzle B, Le JM, et al. High density DNA methylation array with single CpG site resolution. Genomics. 2011;98(4):288–95.

23. Sandoval J, Heyn H, Morán S, Serra-Musach J, Pujana MA, Bibikova M, et al. Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics. 2011;6(6):692–702.

24. Youssfi P, Huen K, Aguilar Schall R, Decker A, Elboudwarej E, Quach H, et al. Considerations for normalization of DNA methylation data by Illumina 450K BeadChip assay in population studies. Epigenetics. 2013;8(11):1141–52.

25. Zhou W, Laid PW, Shen H. Comprehensive characterization, annotation and innovative use of human DNA methylation BeadChip probes. Nucleic Acids Res. 2017;45(4):e29.

26. Chen YA, Lemire M, Choufani S, Butcher DT, Grafodatskaya D, Zanke BW, et al. Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray. Epigenetics. 2013;8(2):203–9.
31. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012;13(7):484–92.

32. Dixon JR, Selvaraj S, Yue F, Kim A, Li Y, Shen Y, et al. Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature. 2012;485(7398):376–80.

33. Shi Y, Guo Z, Su X, Meng L, Zhang M, Sun J, et al. DeepAntigen: a novel method for neoantigen prioritization via 3D genome and deep sparse learning. Bioinformatics. 2020;36(19):4894–901.

34. Dekker J, Marti-Renom MA, Mirny LA. Exploring the three-dimensional organization of genomes: interpreting chromatin interaction data. Nat Rev Genet. 2013;14(6):390–403.

35. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–7.

36. Klein G, Daubney A. The cartoon introduction to statistics: Hill and Wang, a Division of Farrar, Straus and Giroux; 2013.

37. Hur JH, Park SY, Dall’Armi C, Lee JS, Di Paolo G, Lee HY, et al. Phospholipase D1 deficiency in mice causes nonalcoholic fatty liver disease via an autophagy defect. Sci Rep. 2016;6:39170.

38. Chen S, Kang Y, Sun Y, Zhong Y, Li Y, Deng L, et al. Deletion of Gab2 in mice protects against hepatic steatosis and steatohepatitis: a novel therapeutic target for fatty liver disease. J Mol Cell Biol. 2016;8(6):492–504.

39. Wang X, Zhao Y, Zhou D, Tian Y, Feng G, Lu Z. Gab2 deficiency suppresses high-fat diet-induced obesity by reducing adipose tissue inflammation and increasing brown adipose function in mice. Cell Death Dis. 2021;12(2):212.

40. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007;45(6):1366–74.

41. Rinella ME, Elias MS, Smolak RR, Fu T, Borensztajn J, Green RM. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res. 2008;49(5):1068–76.

42. Hyun J, Jung Y. DNA methylation in nonalcoholic fatty liver disease. Int J Mol Sci. 2020;21(12):8138.

43. Nitert MD, Dayeh T, Volkov P, Elgzyri T, Hall E, Nilsson E, et al. Impact of an exercise intervention on DNA methylation in skeletal muscle from first-degree relatives of patients with type 2 diabetes. Diabetes. 2012;61(12):3322–32.

44. Ronn T, Volkov P, Davegardh C, Dayeh T, Hall E, Olsson AH, et al. A six months exercise intervention influences the genome-wide DNA methylation pattern in human adipose tissue. PLoS Genet. 2013;9(6):e1003572.

45. Shai I, Schwarzfuchs D, Henkin Y, Shahar DR, Witkov S, Greenberg I, et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med. 2008;359(3):229–41.

46. Bazzano LA, Hu T, Reynolds K, Yao L, Bunol C, Liu Y, et al. Effects of low-carbohydrate and low-fat diets: a randomized trial. Ann Intern Med. 2014;161(5):309–18.

47. Eckard C, Cole R, Lockwood J, Torres DM, Williams CD, Shaw JC, et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Therap Adv Gastroenterol. 2013;6(6):249–59.

48. Goodpaster BH, Delany JP, Otto AD, Kuller L, Vockley J, South-Paul J, et al. Effects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults: a randomized trial. JAMA. 2010;304(16):1795–802.

49. Gepner Y, Shleif L, Komy O, Cohen N, Schwarzfuchs D, Bril N, et al. The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content. J Hepatol. 2019;71(2):379–88.

50. Bozetto L, Prinster A, Annuzzi G, Costagliola L, Mangione A, Vitelli A, et al. Liver fat is reduced by an isoenzymatic MUFA diet in a controlled randomized study in type 2 diabetic patients. Diabetes Care. 2012;35(7):1429–35.

51. Cheng J, Zhong Y, Chen S, Sun Y, Huang L, Kang Y, et al. Gab2 mediates hepatocellular carcinogenesis by integrating multiple signaling pathways. FASEB J. 2017;31(12):5530–42.

52. Yu M, Luo J, Yang W, Wang Y, Mizuki M, Kanakura Y, et al. The scaffolding adapter Gab2, via Shp-2, regulates kit-evoked mast cell proliferation by activating the Rac/JNK pathway. J Biol Chem. 2006;281(39):28615–26.

53. Nishida K, Wang L, Morii E, Park SJ, Narimatsu M, Itoh S, et al. Requirement of Gab2 for mast cell development and KitL/c-Kit signaling. Blood. 2002;99(5):1866–9.

54. Lehmann-Werman R, Magenheim J, Moss J, Neiman D, Abraham O, Piyanzin S, et al. Monitoring liver damage using hepatocyte-specific methyltransferase markers in cell-free circulating DNA. JCI Insight. 2018;3(12):e120687.

55. Reuben A. Hy’s law. Hepatology. 2004;39(2):S74–8.

56. Nano J, Ghanbari M, Wang W, de Vries PS, Dhana K, Muka T, et al. Epigenome-wide association study identifies methylation sites associated with liver enzymes and hepatic steatosis. Gastroenterology. 2017;153(4):1096–106.

57. Wahl S, Drong A, Lehne B, Loh M, Scott WR, Kunze S, et al. Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity. Nature. 2017;541(7635):81–6.

58. Cokus SJ, Feng S, Zhang X, Chen Z, Merialdo B, Haudenschild CD, et al. Shotgun bisulphite sequencing of the Arabidopsis genome reveals DNA methylation patterning. Nature. 2008;452(7184):215–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.